Vicore Pharma grants Nippon Shinyaku exclusive rights to develop and commercialize C21 therapy for IPF in Japan, in a USD 10m upfront deal plus milestones and royalties.

Vicore Pharma Holding, a Swedish company specializing in developing drugs for idiopathic pulmonary fibrosis, has entered into an exclusive license agreement with Nippon Shinyaku, a leading Japanese pharmaceutical company, to develop and commercialize C21 in Japan. C21 is a potentially transformative therapy for the treatment of the disease. Vicore will receive an upfront payment of USD 10 million and is entitled to up to USD 275 million in milestones, along with tiered royalty payments.

February 09, 2024
4 Articles

Further Reading